

Trend Macrolytics, LLC Donald Luskin, Chief Investment Officer Thomas Demas, Managing Director Michael Warren, Energy Strategist

Data Insights: Covid-2019 Monitor

Thursday, July 29, 2021

The global scorecard



For more information contact us:

Donald Luskin: 312 273 6766 don@trendmacro.com Thomas Demas: 704 552 3625 tdemas@trendmacro.com

Copyright 2021 Trend Macrolytics LLC. All rights reserved. This document is not to be forwarded to individuals or organizations not authorized by Trend Macrolytics LLC to receive it. For information purposes only; not to be deemed to be recommendations for buying or selling specific securities or to constitute personalized investment advice. Derived from sources deemed to be reliable, but no warranty is made as to accuracy.

The US scorecard

The ten worst US states														
New cases		New Deaths		New in h	nospital	<mark>ipital Ourne ca</mark> r		es Quine deaths		Cume in hospital		Hospital use	ICU use	
Æ	+10,452	W	+98	Æ	+433	CA	3,935,590	CA	64,341	TX	264,374	RI 94%	MO 30%	
TX	+9,288	TX	+71	KY	+247	TX	3,105,208	NY	53,623	CA	247,246	MA 85%	AR 27%	
CA	+7,689	CA _	+49	GA	+196	FL.	2,513,058	TX	53,149	FL.	203,472	MO 84%	NV 24%	
LA	+4,699	H. Ar	+41	IX	+182	NY	2,142,132	H.	38,692	NY	138,130	MD 84%	HL 23%	
GA	+3,828	UK NO	+31	CA	+125	IL Di	1,415,572	PA	27,838	GA	112,999	HL 83%	0 UI 22%	
MO	+2,835	MO NV	+24	AL	+80	PA	1,220,720	NJ	20,589	PA	92,705	GA 82%	NIS 22%	
AL	+2,720		+20		+ 60	GA AL	1,171,233		20,000	UT II	09,340 94 225	PA 61%	0 IA 10%	
	+2,000		±16		+30		1,120,420	M	21,004	IL KV	0 1 ,230 81 212	NV 80/0	ο UK 10/ο ΔK 17%	
IΔ	+2,220		+10 +14	MO	+ 40	NI	1,041,009	0H	21,100	M	74.003	MN 70%	WY 15%	
U A	+48.534		+382	NIO	+1476	140	18712517	ui	353,394	IVII	1.387.721		WT 1070	
	1 10,001		1002		1,170		10,112,011		000,001		1,001,121			
All states	+79.223		+428		+1769	All states	34.672.690		611.801		2.470.591	All states 70%	67%	
Topten	61%		89%		83%	Topten	54%		58%		56%	Median 73%	8%	
						•			So	me states n	ot reporting			
Five most improved US states														
Fewer d	aily cases			Fe	ewer new dea	aths		Fewer n	ew hospita	lizations		Most pop im	n unui ty growth	
TX	-3,264				KS	-248			NV	-55		G4	+50 bp	
CA	-2,602				MO	-38			AZ	-49		NJ	+30 bp	
LA	-2,119				СН	-23			KS	-36		U	+30 bp	
MI	-2,069				MI	-19			υī	-28		MF	• +20 bp	
MN	-410				AZ	-10			TN	-23		NH	l +20 bp	
350,000 _T													г 12%	
300,000 -	Unit	United States					As of Jul 28		11				- 10%	
	1064.	496 bp of p	opulation	nfected						34,6	72,690 cases	s cumulative		
250.000 -	18.78	3 bp of pop	ulation fat	alities					44		+68,771 case	es today		
sc 	38.1 r	nedian pop	ulation age	9				- M		0	[700	- 8%	
death	91.5%	6 Delta vari	ant share					MH		Cume	ratality rate 1.	/0%		
귵 200,000 -								1 I I I V					ase	
ases			and the second				٨	MĽ	M A.	2-we	ek fatality rate	e 1.51% –	- 6% fata	
8 ≩ 150.000 -			1		N.		N						ity ra	
≥ looted					\mathcal{N}			1	'[611,8	301 deaths cu	imulative	te	
Dai					A.		Į.			1	387 deatris to	bday	- 4%	
100,000 -			7-day moving	average cases		******				N				
					- \ .		······				LIAN .			
50.000					NAN'	M.	ANN S	· · · · · · · · · · · · · · · · · · ·		WW	MMM	Δ	2%	
50,000 -			-		<i>/</i>	"MMM	WV.				ייויוי	M X	M	
		1	~~~~	mm	a	V.						MMILLA		
_								~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	<u> </u>	<u> </u>		4144404		
Dec 3	51 Feb	19	Apr 9	May 29	Jul 18	Sep 6	Oct 26	Dec 1	.b Fe	eb 3	Mar 25	May 14 Jul 3		

Source: Johns Hopkins, Dept. of Health and Human Services, CDC, TrendMacro calculations

Rolling	g out th	e vacci	ines in	the US	and t	ne worl	d	-					
Administe	Administered Cumulative		ilative				loday			Full	Partial		
Doses		353,231,943						+0.762		US	48.9%	56.7%	
T	One dose		dose	% Pop li		nune	% pop	New immune today		UK	55.4%	68.8%	
Total popu	opulation 194,249,154		94,249,154	58%	1	67,860,405	50%	+0.278 million		France	45.3%	59.1%	
Age 12 to	12 to 17 10,468,788		10,468,788	41%		8,113,666	32%	+0.045 million		Spain	56.5%	67.0%	
Age 18 to 64 132,923,		32,923,607	02%		14,407,651	50%	+0.199 million		Germany	50.6%	60.9%		
Age 65 and over		;	00,633,396	93%		45,209,424	83%	83% +0.035 million		Italy	50.4%	02.0%	
J&J 494								3 immune in		Australia	13.9%	31.0%	
470		r		_		117	l da	IVS		Conodo	01.0% 57.4%	71.00/	
Moderna 40% Pfizer		St	ate	Be	əst	by lon 15		· J O		Japan	07.4%	20.00/	
		At least par	tial immunity			61.8% of	opulation	>18 immu	nized	Δfrica	1.6%	3 2%	
	56%		as % population		ddle	11.8% pre	viously tes	ted nositiv	<u>a</u>	India	7.1%	25.6%	
		Full immunity				73.6%	vs 60% ac	ult herd in	- nmunitv*	Brazil	18.6%	48.1%	
AK		as % population		W	orst					Global data differ	rs from sources,	timing	
51.2%						WI		As of Jul 28		China NA	ME	1	
45.4%						55.3%					68.1%		
10.170						51.6%					63.3%		
	WA	ID	MT	ND	MN	IL	MI	1	NY	VT	NH	1	
	63.6%	40.9%	49.1%	45.2%	58.5%	61.8%	52.9%		62.7%	75.3%	64.5%		
	57.4%	37.2%	44.1%	40.0%	53.6%	48.2%	48.7%		56.8%	67.4%	58.2%		
	OR	NV	WY	SD	IA	IN	OH	PA	NJ	MA			
	60.4%	53.1%	41.4%	52.4%	53.0%	46.9%	49.6%	65.2%	65.6%	72.4%			
	55.8%	44.1%	36.5%	46.8%	49.5%	44.0%	46.3%	52.0%	58.1%	63.7%		_	
	CA	UT	CO	NE	M0	KY	WV	VA	MD	CT	RI		
	64.3%	51.9%	59.9%	53.5%	48.2%	51.6%	45.9%	61.3%	64.4%	69.5%	66.8%		
	52.5%	44.7%	54.2%	49.3%	41.0%	45.3%	39.0%	54.3%	58.6%	63.0%	61.2%		
		AZ	NM	KS	AR	TN	NC	SC	DC	DE		-	
		52.7%	65.0%	52.9%	46.0%	44.3%	50.8%	46.3%	63.6%	60.3%			
		45.1%	56.8%	45.0%	36.1%	38.9%	43.6%	40.4%	54.5%	52.5%			
				OK	LA	MS	AL	GA					
				47.4%	41.5%	39.3%	42.7%	45.9%					
	1			40.0%	36.7%	34.4%	34.2%	38.5%		1 r	חח	1	
/1.2%				51.1%					57.0%				
53.4%				43.0%					48.0%	1 I	59.6%		
The demo	graphics of	US vaccinat	tion										
60% т				60%				90% -					
51.4% of females immunized					48.7% of wh	nites immunize	ed	0.000	0.3% of age <12 immunized				
50%	50% 47.3% of males			50%	36.2% of Af	rican America	ns	80% -	28.1% 12-1	5			
					45.0% of Hi	spanics		70% -	39.6% 16-1	7			
40%				40%	53.8% of As	sians		60% -	43.4% 18-2	4			
							50%	50% 48.4% 25-39					
30% -				30%				50%	57.4% 40-49				
								40% -		4			
20%				20% -				30% -	30% 81.6% 65-74				
							20%						
10%			10%										
							10%						
+		N N	N N	-				+					
21202212	62, 102, 102,	1202, 1202, 120	22,2022	212022	202, 1202, 120	2,202,202,1	202, 2021	212020	1202, 1202, 120	2, 202, 202, 1	202, 1202,		
212, 112,	212,312, AL	6/2 6/2 1	12.	212, 113	212 312 0	12, 212, 012	112	21/2, 112	212 312 0	12, 212, 0123	112		
Source [.]	CDC. CDC	. Our Wo	orld in Dat	ta. Trend	Macro ca	alculation	S						





Case-fatality rate



Source: Johns Hopkins, Covid Act Now, TrendMacro calculations



Source: Distributions <u>CDC</u>, Comorbidities <u>CDC</u>, TrendMacro calculations

Recommended reading

<u>COVID-19 and education: The lingering effects of</u>

unfinished learning

ma Dorn, Bryan Hancock, Jimmy Sarakatsannis, and Ellen Viruleg *McKinsey & Company* July 27, 2021

The Cost of the School Shutdowns

Wall Street Journal July 28, 2021

Covid Will Increase Life Expectancy

David Colander *Wall Street Journal* July 28, 2021

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

Kristen W. Cohen et al. *Outbreak News Today* July 14, 2021

<u>Eight reasons why the UK's coronavirus cases appear</u> to be falling

Graham Lawton *NewScientist* July 27, 2021

Meme of the day



Source: Our beloved clients, Power Line blog "The Week in Pictures" and CTUP







The coronavirus <u>mortality</u> accelerometer ... tracking the world's fatality curves *Share of deceased population from day of first fatality, log scale*

Source: Johns Hopkins, TrendMacro calculations



"Exponential"? Our most reliable evidence of the rate of spread of Covid-2019

Requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in new cases *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst



Alt requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in pos tests *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst



Source: Covid Act Now, TrendMacro calculations



Source: Johns Hopkins, TrendMacro calculations



Source: Johns Hopkins, TrendMacro calculations



Patient zero... and then everyone else

Source: Johns Hopkins, TrendMacro calculations

Impact in the largest economies









Source: Johns Hopkins, TrendMacro calculations

Impact in other hot-spots





Source: Johns Hopkins, TrendMacro calculations



Source: Johns Hopkins, TrendMacro calculations

